Immuron Limited (IMRN)
| Market Cap | 7.77M -11.7% |
| Revenue (ttm) | 5.34M +5.9% |
| Net Income | -2.55M |
| EPS | -0.34 |
| Shares Out | 322.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.8499 |
| Day's Range | n/a |
| 52-Week Range | 0.6765 - 1.9900 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About IMRN
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an... [Read more]
Financial Performance
In fiscal year 2026, Immuron's revenue was 7.71 million, an increase of 5.85% compared to the previous year's 7.29 million. Losses were -3.68 million, -29.45% less than in 2025.
Financial numbers in AUD Financial StatementsNews
Immuron Limited Announces Q1 Global Sales of AUD$2.2 million
Immuron Limited announced its unaudited sales results for the quarter ending September 30, 2026, reporting global Q1 sales of AUD$2.2 million. This represents a 9% increase compared to the prior compa...
Immuron continued quarterly sales growth
Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative per...
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerg...
Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down
(RTTNews) - Immuron Limited (IMRN) announced that results from its Phase 2 clinical trial evaluating once-daily oral Travelan have been published in the journal Scientific Reports, providing further i...
Immuron’s Travelan Phase 2 study results published
Immuron (IMRN) announced that data from its Phase 2 clinical trial of once-daily oral Travelan has been published in the Nature Journal, Scientific Reports. The clinical study, partially funded by…
Travelan® Phase 2 Study Results Published
MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been publish...
Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up
(RTTNews) - Australian biopharmaceutical company Immuron Ltd. (IMC.AX, IMRN), announced on Friday that it has signed an exclusive distribution deal with Sweden's Calmino group AB to launch its digesti...
Immuron to launch Proibs in the U.S.
Immuron (IMRN) announces that it has executed an exclusive distribution agreement for Proibs in the United States with Calmino group AB. Immuron launched Proibs in Australia during FY26. Flavio Palumb...
Immuron to launch PROIBS® in the United States
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the Uni...
Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges
(RTTNews) - Immuron Limited (IMRN,IMC.AX), a commercial and clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibody products, reported p...
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued...
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immur...
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-mont...
Immuron Double Digit 3Q Sales Growth
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD...
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12...
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chie...
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-mo...
Immuron Reports Continued Sales Growth
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prio...
Why Is Immuron Stock (IMRN) Down Today?
Immuron stock fell on Wednesday alongside the release of new clinical trial data.
Immuron anounces new DoD award and clinical trial updates
Immuron (IMRN) announced a new research agreement with the Naval Medical Research Command – NMRC – and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA
Immuron announces FDA approval of IND for IMM-529
Immuron (IMRN) is pleased to announce that the United States FDA has approved Immuron’s Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed. The company
Immuron: FDA Approves IND Application For IMM-529
(RTTNews) - Immuron (IMRN) announced the FDA has approved Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed. The company plans to initiate a Phase 2 clinical ...
Immuron IMM-529 IND approved by FDA
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) f...
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-mont...
Immuron Announces Rise In Global Revenue For Q1
(RTTNews) - Immuron Ltd. (IMRN), an Australian biopharmaceutical company, Monday reported its first-quarter global sales growth of Travelan, an over-the-counter immune supplement.